Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients (≥18 years of age) with metastatic (Stage IV) colorectal adenocarcinoma confirmed either histologically or cytologically, with measurable metastatic disease according to RECIST v. 1.1
Patients must have PD after receiving the approved standard therapies
Patients must have ECOG PS of 0 or 1 and a life expectancy of at least 3 months
Adequate bone marrow, liver and renal function
Women of childbearing potential and men must agree to use adequate contraception
You may not be if
Unresolved toxicity greater than Grade 1 from prior treatment for mCRC
Previous (within 28 days) or concomitant participation in another clinical study with investigational medicinal product(s)
Subjects unable to swallow oral medications
Any malabsorption condition
Any medical or surgical conditions within 28 days before start of regorafenib that will interfere with patient's participation in the study
Clareo Health | Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).
